The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).
Eric P. Winer
Research Funding - Exelixis
Sara Tolaney
Research Funding - Exelixis
Hovav Nechushtan
Research Funding - Exelixis
Raanan Berger
Research Funding - Exelixis
Razelle Kurzrock
Research Funding - Exelixis
Ilan-Gil Ron
Research Funding - Exelixis
Patrick Schoffski
No relevant relationships to disclose
Ahmad Awada
Research Funding - Exelixis
Christopher A. Yasenchak
Research Funding - Exelixis
Howard A. Burris
Research Funding - Exelixis
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Teresa Rafferty
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis